From Chronodisruption to Sarcopenia: The Therapeutic Potential of Melatonin
Biomolecules · 2023
DOI: 10.3390/biom13121779 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2023. Verfasst von José Fernández-Martínez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación Biomédica, Facultad de Medicina, Departamento de Fisiología, Instituto de Biotecnología, Parque Tecnológico de Ciencias de la…. Hauptthemen laut MEDLINE: Sarcopenia, Melatonin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Ministerio de Universidades, Spain.
Abstract (Originalsprache)
Sarcopenia is an age-related condition that involves a progressive decline in muscle mass and function, leading to increased risk of falls, frailty, and mortality. Although the exact mechanisms are not fully understood, aging-related processes like inflammation, oxidative stress, reduced mitochondrial capacity, and cell apoptosis contribute to this decline. Disruption of the circadian system with age may initiate these pathways in skeletal muscle, preceding the onset of sarcopenia. At present, there is no pharmacological treatment for sarcopenia, only resistance exercise and proper nutrition may delay its onset. Melatonin, derived from tryptophan, emerges as an exceptional candidate for treating sarcopenia due to its chronobiotic, antioxidant, and anti-inflammatory properties. Its impact on mitochondria and organelle, where it is synthesized and crucial in aging skeletal muscle, further highlights its potential. In this review, we discuss the influence of clock genes in muscular aging, with special reference to peripheral clock genes in the skeletal muscle, as well as their relationship with melatonin, which is proposed as a potential therapy against sarcopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Investigación Biomédica, Facultad de Medicina, Departamento de Fisiología, Instituto de Biotecnología, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, 18016 Granada, Spain.
- Instituto de Investigación Biosanitaria (Ibs.Granada), Hospital Universitario San Cecilio, 18016 Granada, Spain.
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Faculty of Life Sciences and Medicine, Northwest University, Xi'an 710069, China.
- Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
- UGC de Laboratorios Clínicos, Hospital Universitario San Cecilio, 18016 Granada, Spain.
ORCID-Profile: José Fernández-Martínez, Yolanda Ramírez-Casas, Paula Aranda-Martínez, Germaine Escames, Darío Acuña-Castroviejo
Förderung
- Instituto de Salud Carlos III
- Ministerio de Universidades, Spain
Zitieren
APA
Fernández-Martínez, J., Ramírez-Casas, Y., Yang, Y., Aranda-Martínez, P., Martínez-Ruiz, L., Escames, G., & Acuña-Castroviejo, D. (2023). From Chronodisruption to Sarcopenia: The Therapeutic Potential of Melatonin. Biomolecules. https://doi.org/10.3390/biom13121779
Vancouver
Fernández-Martínez J, Ramírez-Casas Y, Yang Y, Aranda-Martínez P, Martínez-Ruiz L, Escames G, et al. From Chronodisruption to Sarcopenia: The Therapeutic Potential of Melatonin. Biomolecules. 2023. doi:10.3390/biom13121779
BibTeX
@article{FernndezMartnez2023,
author = {Fernández-Martínez, José and Ramírez-Casas, Yolanda and Yang, Yang and Aranda-Martínez, Paula and Martínez-Ruiz, Laura and Escames, Germaine and Acuña-Castroviejo, Darío},
title = {From Chronodisruption to Sarcopenia: The Therapeutic Potential of Melatonin},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13121779}
}
EUVIMED